Dr. Peter Frederick, MD

Claim this profile

Roswell Park

Studies Endometrial Cancer
Studies Uterine Cancer
4 reported clinical trials
15 drugs studied

Area of expertise

1Endometrial Cancer
Peter Frederick, MD has run 3 trials for Endometrial Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive
2Uterine Cancer
Peter Frederick, MD has run 3 trials for Uterine Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive

Affiliated Hospitals

Image of trial facility.
Roswell Park
Image of trial facility.
Roswell Park Cancer Institute

Clinical Trials Peter Frederick, MD is currently running

Image of trial facility.

Targeted Therapy + Atezolizumab

for Endometrial Cancer

This trial tests drugs that target cancer cells, sometimes combined with an immune-boosting drug called atezolizumab. It focuses on patients with endometrial cancer that has returned or is persistent. The drugs are chosen based on the genetic profile of the patient's tumor to improve effectiveness.
Recruiting1 award Phase 1 & 25 criteria
Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3

More about Peter Frederick, MD

Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Peter Frederick, MD has experience with
  • Carboplatin
  • Paclitaxel
  • Atezolizumab
  • Bevacizumab
  • Inavolisib
  • Ipatasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Peter Frederick, MD specialize in?
Is Peter Frederick, MD currently recruiting for clinical trials?
Are there any treatments that Peter Frederick, MD has studied deeply?
What is the best way to schedule an appointment with Peter Frederick, MD?
What is the office address of Peter Frederick, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security